OKYO Pharma Bullish Thesis

OKYO Pharma recently released a presentation providing an update on its progress. Here is a brief summary of the presentation:

OKYO Pharma’s presentation highlights their key drug candidate, OK-101, developed to treat Dry Eye Disease (DED) and Neuropathic Corneal Pain (NCP). OK-101 is a lipid-conjugated chemerin peptide designed to address both inflammation and pain associated with DED. Preclinical studies in animal models have demonstrated that OK-101 reduces ocular inflammation, restores goblet cell loss, and minimizes neuropathic pain. The drug is administered topically, which reduces systemic exposure and allows for a more streamlined clinical trial process. A Phase 2 trial for DED was initiated in May 2023, with positive top-line data released in January 2024. OKYO Pharma plans to start a Phase 2 trial for NCP in Q2 2024.

The global market for DED is projected to reach approximately $11 billion by 2030, underscoring the significant need for more effective treatments. Current standard care for DED, such as Restasis and Cequa, have limitations including delayed efficacy and side effects, driving demand for better therapeutic options. OK-101’s novel mechanism targets the chemerin receptor, enhancing anti-inflammatory responses and improving tear film stability. The company’s intellectual property portfolio secures OK-101’s use in treating DED and NCP until at least 2039. OKYO Pharma’s leadership team, with extensive experience in pharmaceutical and biotechnology industries, is poised to advance OK-101 through the regulatory and clinical landscapes.

OKYO_-Deck_MAY-2024_FINAL-Non-Con